Damaschin, Carla
Goergen, Helen
Kreissl, Stefanie
Plütschow, Annette
Breywisch, Frank
Mathas, Stephan http://orcid.org/0000-0001-9626-1413
Meissner, Julia
Sökler, Martin
Topp, Max S.
Vucinic, Vladan
Zimmermann, Andreas
von Tresckow, Bastian
Fuchs, Michael
Engert, Andreas
Borchmann, Peter
Eichenauer, Dennis A. http://orcid.org/0000-0002-1927-3514
Funding for this research was provided by:
Takeda Pharmaceutical Company Limited | Takeda Oncology (Millennium Grant X25001)
Takeda Pharmaceuticals U.S.A. (Millennium Grant X25001)
Article History
Received: 7 June 2021
Revised: 8 August 2021
Accepted: 10 August 2021
First Online: 18 August 2021
Competing interests
: BvT is an advisor or consultant for Amgen, BMS/Celgene, Novartis, Pentixafarm, Pfizer, Takeda, Merck Sharp & Dohme, and Gilead Kite; has received honoraria from Novartis, Roche Pharma AG, Takeda, and Merck Sharp & Dohme; reports research funding from Novartis (Inst), Merck Sharp & Dohme (Inst), and Takeda (Inst); and reports travel support from AbbVie, AstraZeneca, KiteGilead, Merck Sharp & Dohme, Takeda, and Novartis. AZ has received honoraria from Takeda; and reports travel grants from Takeda. All other authors report no potential conflicts of interest.